Bimekizumab in the Treatment of Plaque Psoriasis

Psoriasis is a chronic systemic inflammatory disease that significatively impairs patients' quality of life. Biological treatments are highly effective and safe and have led to breakthroughs in the management of patients with moderate-to-severe psoriasis. However, therapeutic response can be un...

Descripción completa

Detalles Bibliográficos
Autores: Camiña-Conforto, Gemma|||0009-0008-2183-9397, Mateu Arrom, Laura|||0000-0001-8522-4748, López Ferrer, Anna|||0000-0002-2121-963X, Puig Sanz, Lluís|||0000-0001-6083-0952
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:303475
Acceso en línea:https://ddd.uab.cat/record/303475
https://dx.doi.org/urn:doi:10.2147/PPA.S350760
Access Level:acceso abierto
Palabra clave:Bimekizumab
Biological therapy
Interleukin-17
Patient compliance
Patient selection
Psoriasis
id ES_8b044b8a26d936a0b135cd17890cc3cb
oai_identifier_str oai:ddd.uab.cat:303475
network_acronym_str ES
network_name_str España
repository_id_str
spelling Bimekizumab in the Treatment of Plaque PsoriasisFocus on Patient Selection and PerspectivesCamiña-Conforto, Gemma|||0009-0008-2183-9397Mateu Arrom, Laura|||0000-0001-8522-4748López Ferrer, Anna|||0000-0002-2121-963XPuig Sanz, Lluís|||0000-0001-6083-0952BimekizumabBiological therapyInterleukin-17Patient compliancePatient selectionPsoriasisPsoriasis is a chronic systemic inflammatory disease that significatively impairs patients' quality of life. Biological treatments are highly effective and safe and have led to breakthroughs in the management of patients with moderate-to-severe psoriasis. However, therapeutic response can be unsatisfactory or lost with time, leading to discontinuation of treatment. Bimekizumab is a humanized monoclonal antibody that specifically inhibits both interleukin (IL)-17A and IL-17F. The efficacy and safety of bimekizumab in moderate-to-severe plaque psoriasis has been demonstrated in Phase 2 and Phase 3 clinical trials. Bimekizumab may offer some advantages over other biological treatments, making it especially indicated for certain patients. This narrative review aims to summarize the latest published evidence on the use of bimekizumab for the treatment of moderate-severe plaque psoriasis, focusing on patient selection and therapeutic perspectives. Bimekizumab has been shown to be more efficacious than adalimumab, secukinumab and ustekinumab in clinical trials, with high estimated probabilities of achieving complete (approximately 60%) or almost complete clearance (approximately 85%) of psoriasis at weeks 10-16, and a good safety profile. Response to bimekizumab is usually fast and maintained in the long term for both biologic-naive patients and those resistant to previous biologic treatments. The usual maintenance dose of 320 mg every 8 weeks makes bimekizumab especially convenient for non-compliant patients. Moreover, the efficacy and safety of bimekizumab have also been demonstrated in psoriasis affecting challenging-to-treat areas, psoriatic arthritis and hidradenitis suppurativa. In conclusion, dual inhibition of IL-17A and IL-17F with bimekizumab is a good therapeutic option for moderate-to-severe psoriasis.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/303475https://dx.doi.org/urn:doi:10.2147/PPA.S350760reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3034752026-06-06T12:50:31Z
dc.title.none.fl_str_mv Bimekizumab in the Treatment of Plaque Psoriasis
Focus on Patient Selection and Perspectives
title Bimekizumab in the Treatment of Plaque Psoriasis
spellingShingle Bimekizumab in the Treatment of Plaque Psoriasis
Camiña-Conforto, Gemma|||0009-0008-2183-9397
Bimekizumab
Biological therapy
Interleukin-17
Patient compliance
Patient selection
Psoriasis
title_short Bimekizumab in the Treatment of Plaque Psoriasis
title_full Bimekizumab in the Treatment of Plaque Psoriasis
title_fullStr Bimekizumab in the Treatment of Plaque Psoriasis
title_full_unstemmed Bimekizumab in the Treatment of Plaque Psoriasis
title_sort Bimekizumab in the Treatment of Plaque Psoriasis
dc.creator.none.fl_str_mv Camiña-Conforto, Gemma|||0009-0008-2183-9397
Mateu Arrom, Laura|||0000-0001-8522-4748
López Ferrer, Anna|||0000-0002-2121-963X
Puig Sanz, Lluís|||0000-0001-6083-0952
author Camiña-Conforto, Gemma|||0009-0008-2183-9397
author_facet Camiña-Conforto, Gemma|||0009-0008-2183-9397
Mateu Arrom, Laura|||0000-0001-8522-4748
López Ferrer, Anna|||0000-0002-2121-963X
Puig Sanz, Lluís|||0000-0001-6083-0952
author_role author
author2 Mateu Arrom, Laura|||0000-0001-8522-4748
López Ferrer, Anna|||0000-0002-2121-963X
Puig Sanz, Lluís|||0000-0001-6083-0952
author2_role author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Bimekizumab
Biological therapy
Interleukin-17
Patient compliance
Patient selection
Psoriasis
topic Bimekizumab
Biological therapy
Interleukin-17
Patient compliance
Patient selection
Psoriasis
description Psoriasis is a chronic systemic inflammatory disease that significatively impairs patients' quality of life. Biological treatments are highly effective and safe and have led to breakthroughs in the management of patients with moderate-to-severe psoriasis. However, therapeutic response can be unsatisfactory or lost with time, leading to discontinuation of treatment. Bimekizumab is a humanized monoclonal antibody that specifically inhibits both interleukin (IL)-17A and IL-17F. The efficacy and safety of bimekizumab in moderate-to-severe plaque psoriasis has been demonstrated in Phase 2 and Phase 3 clinical trials. Bimekizumab may offer some advantages over other biological treatments, making it especially indicated for certain patients. This narrative review aims to summarize the latest published evidence on the use of bimekizumab for the treatment of moderate-severe plaque psoriasis, focusing on patient selection and therapeutic perspectives. Bimekizumab has been shown to be more efficacious than adalimumab, secukinumab and ustekinumab in clinical trials, with high estimated probabilities of achieving complete (approximately 60%) or almost complete clearance (approximately 85%) of psoriasis at weeks 10-16, and a good safety profile. Response to bimekizumab is usually fast and maintained in the long term for both biologic-naive patients and those resistant to previous biologic treatments. The usual maintenance dose of 320 mg every 8 weeks makes bimekizumab especially convenient for non-compliant patients. Moreover, the efficacy and safety of bimekizumab have also been demonstrated in psoriasis affecting challenging-to-treat areas, psoriatic arthritis and hidradenitis suppurativa. In conclusion, dual inhibition of IL-17A and IL-17F with bimekizumab is a good therapeutic option for moderate-to-severe psoriasis.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/303475
https://dx.doi.org/urn:doi:10.2147/PPA.S350760
url https://ddd.uab.cat/record/303475
https://dx.doi.org/urn:doi:10.2147/PPA.S350760
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412776162623488
score 15,81155

Similares en LA Referencia